<ul data-eligibleForWebStory="false"><li>Aurobindo Pharma based in Hyderabad will manufacture and supply a long-acting injectable HIV treatment across 133 countries, including low- and middle-income markets.</li><li>The treatment provides an alternative to daily pills by offering patients the option of receiving one injection every one or two months.</li><li>ViiV Healthcare and the Medicines Patent Pool have updated their voluntary licensing agreement to include patents for a long-acting HIV treatment in compliance with updated WHO guidance.</li><li>The aim is to increase access to long-acting HIV treatment in various countries worldwide, especially for those facing challenges with oral regimens.</li></ul>

Aurobindo Pharma to manufacture long-acting HIV treatment for global markets

Discover more